Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

553 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Mancia G, et al. Among authors: verdecchia p. Circulation. 2011 Oct 18;124(16):1727-36. doi: 10.1161/CIRCULATIONAHA.110.008870. Epub 2011 Sep 26. Circulation. 2011. PMID: 21947289 Clinical Trial.
Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement.
O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P; European Society of Hypertension Working Group on Blood Pressure Monitoring. O'Brien E, et al. Among authors: verdecchia p. J Hypertens. 2005 Apr;23(4):697-701. doi: 10.1097/01.hjh.0000163132.84890.c4. J Hypertens. 2005. PMID: 15775768 No abstract available.
Inappropriate left ventricular mass: Reliability and limitations of echocardiographic measurement for risk stratification and follow-up in single patients.
Muiesan ML, de Simone G, Ganau A, Longhini C, Verdecchia P, Mancia G, Agabiti-Rosei E; Working Group on Heart and Hypertension of Italian Society of Hypertension. Muiesan ML, et al. Among authors: verdecchia p. J Hypertens. 2006 Nov;24(11):2293-8. doi: 10.1097/01.hjh.0000249709.44016.15. J Hypertens. 2006. PMID: 17053553 Clinical Trial.
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
[The ONTARGET trial].
Verdecchia P, Terrosu P. Verdecchia P, et al. G Ital Cardiol (Rome). 2009 Feb;10(2):67-72. G Ital Cardiol (Rome). 2009. PMID: 19348142 Italian. No abstract available.
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators. Sleight P, et al. Among authors: verdecchia p. J Hypertens. 2009 Jul;27(7):1360-9. doi: 10.1097/HJH.0b013e32832d7370. J Hypertens. 2009. PMID: 19506526 Clinical Trial.
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators. Verdecchia P, et al. Circulation. 2009 Oct 6;120(14):1380-9. doi: 10.1161/CIRCULATIONAHA.109.865774. Epub 2009 Sep 21. Circulation. 2009. PMID: 19770395 Clinical Trial.
553 results